Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 13;6(3):129.
doi: 10.3390/tropicalmed6030129.

High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil

Carlos Henrique Alencar  1   2 , Luciano Pamplona de Góes Cavalcanti  1   2   3 , Magda Moura de Almeida  1   4 , Patrícia Pereira Lima Barbosa  1 , Kellyn Kessiene de Sousa Cavalcante  1   4 , Déborah Nunes de Melo  1 , Bruno Cavalcante Fales de Brito Alves  3 , Jorg Heukelbach  1
Affiliations

High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil

Carlos Henrique Alencar et al. Trop Med Infect Dis. .

Abstract

In Brazil, the SARS-CoV-2 vaccination program has so far prioritized people over 75 years of age. By the end of March 2021, in Ceará State, a total of 313,328 elderly people had received at least one dose of vaccine (45% Oxford-AstraZeneca/Fiocruz and 55% CoronaVac-Sinovac/Butantan), and 159,970 had received two doses (83% CoronaVac-Sinovac/Butantan and 17% Oxford-AstraZeneca/Fiocruz). After a single dose, there was already a significant reduction in COVID 19-related deaths (protection ratio: 19.31 (95% CI: 18.20-20.48), attributable protection ratio: 94.8%); higher protection ratios were observed after the application of two doses of the vaccine (132.67; 95% CI: 109.88-160.18), with an attributable protection ratio of 99.2%. SARS-CoV-2 vaccines are highly effective in reducing the number of COVID-19-related deaths in over 75-year-olds in Brazil, one of the hardest hit countries by the current pandemic.

Keywords: COVID-19; COVID-19 vaccines; SARS-CoV-2; epidemiology; mortality; public health.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hodgson S.H., Mansatta K., Mallett G., Harris V., Emary K.R., Pollard A.J. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 2021;21:e26–e35. doi: 10.1016/S1473-3099(20)30773-8. - DOI - PMC - PubMed
    1. Cook T., Roberts J. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19. Anaesthesia. 2021;76:608–616. doi: 10.1111/anae.15442. - DOI - PMC - PubMed
    1. Gee J. First month of COVID-19 vaccine safety monitoring—United States, 14 December 2020–13 January 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70 doi: 10.15585/mmwr.mm7008e3. - DOI - PMC - PubMed
    1. Brasil COVID19—Painel Coronavírus 2021. [(accessed on 29 June 2021)]; Available online: https://covid.saude.gov.br.
    1. Lemos D.R.Q., D’angelo S.M., Farias L.A.B.G., Almeida M.M., Gomes R.G., Pinto G.P., Cavalcante Filho J.N., Feijão L.X., Cardoso A.R.P., Lima T.B.R. Health system collapse 45 days after the detection of COVID-19 in Ceará, Northeast Brazil: A preliminary analysis. Rev. Soc. Bras. Med. Trop. 2020;53:e20200354. doi: 10.1590/0037-8682-0354-2020. - DOI - PMC - PubMed

LinkOut - more resources